CSL Ltd shares are having a choppy session on Tuesday.
The CSL share price climbed as high as $177 in early trade but has since given back those gains, now flat at $174.30.
CSL shares have had a much better run over the past month after a tough first half of 2026.
According to The Australian, Barrenjoey has upgraded CSL to overweight with a $180 price target.
TipRanks shows 11 recent analyst ratings on CSL, with 5 buys and 6 holds. The average 12-month price target is $172.92, which is where the shares are trading now.
Jarden is at $207, Morgans is at $187.71, Canaccord is at $185, Morgan Stanley is at $182, and UBS is at $181.
At the lower end, Citi has a $160 target, Bell Potter is at $150, and Macquarie is down at $133.
FY26 revenue came in at US$15.8 billion, down 1% in constant currency, while underlying NPATA fell 2% to US$3.1 billion.
Immunoglobulin revenue rose 7% over the year, channel inventory normalisation was completed, and CSL delivered US$176 million of savings during FY26.
Shortened to 1 minute
of reading, this version reads 11.3 on the Niral Score.
You are reading our version, not theirs.
This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with
verdicts and loaded words taken out. Plain description stays, and so do adjectives
that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations
are theirs — quotations are never edited — and the indicators beside it measure
this version. Hover or tap Adjectives to see every one left in the text.
How this outlet filed it, and how we rewrote it
No other newsroom we read has filed on this event, so there is nothing to compare it with yet.
Readers can ask a question about this story here.
Questions and answers are for subscribers.
Sign in
to read them.
Comments are read before they appear where anything in them needs a person to look.
Nothing posted here is ever deleted; a comment taken down keeps its text and the reason,
so the decision can be looked at again. How this works